Drug delivery solutions
Transforming bold ideas into breakthrough drug delivery solutions.
From blank sheet to clinical reality, we create groundbreaking solutions to solve the toughest drug delivery challenges. With deep engineering, human factors, and scientific expertise, we guide you through every stage of device development - from early exploration to manufacturing and final launch. Backed by an extensive track record we expertly navigate constraints to develop robust, efficient, scalable devices - enabling the delivery of transformative therapies and enhanced patient experiences.
We’ve partnered with nine of the top ten global pharmaceutical companies
Bringing life-changing devices or combination drug delivery products to market is a complex task, but TTP has the expertise and experience to help you accelerate development, manage risks, and balance trade-offs at every stage. We’ve played a critical role in developing more than 70 innovative drug delivery systems, from injectable devices and microneedles to complex infusion pumps.
Any delay to launch a medical product can be extremely costly. That’s why we focus on rapid, agile device development, assembling small project teams of multidisciplinary experts who can quickly adapt to each project’s unique demands, resolve complex challenges fast and prevent downstream delays.
We work collaboratively to devise high-impact drug delivery solutions, applying first-principles thinking and scientific rigour to ensure robustness in real-use scenarios. Through probabilistic methods, we account for variability in materials, processes, and environments, identifying potential issues early to set specifications that ensure your device will perform reliably throughout its lifecycle.
That’s why the world’s most ambitious pharmaceutical and biotech companies trust us to deliver their most critical projects.
Together, we’ll transform your bold ideas into breakthrough drug delivery solutions.
Discover how TTP’s first-principles R&D approach helped AstraZeneca to secure FDA approval for Symbicort®—a world-leading asthma therapy generating over $2bn annually—by rapidly delivering a cost-effective, reliable pMDI dose counter that outperformed competitors. Learn more.
TTP have been an invaluable long-term partner for AstraZeneca. They have both the deep expertise and creativity to generate innovative concepts, and the horsepower to accelerate these through design verification.
Dan Deaton
Executive Director, Patient Experience & Innovation at AstraZeneca
TTP has been an incredible partner, complementing our expertise and delivering designs from white board to moulded functional prototypes. With TTP’s support, Achilles is scaling our manufacturing process and bringing transformative therapies from bench to bedside. The TTP team has shown the same level of excitement as us in getting these therapies to the people who need them.
Ed Samuel
EVP Technical Operations
When we received the new moulded parts incorporating TTP’s recommendations, all of them performed as intended and within specification. We were really excited.
Justin Creel
Vice President of Device Development
Advancing injectable device innovation
TTP has a proven track record in injectable device development, playing a key role in more than eight mechanical injection devices now on the market, with many more in the pipeline.
We’ve supported clients on a range of projects, from variable dose pens and autoinjectors to ophthalmic injectors and wearable devices.
TTP’s current work is helping address many of the challenges that the industry is currently facing, such as:
Delivering more complex formulations. Taking a scientific approach to model and investigate performance issues related to primary pack interactions, including viscous suspensions, needle clogging and tissue interactions.
Designing for scale. We’ve helped pharma companies resolve reliability and performance issues in pen and autoinjector systems during scale-up, gaining deep insights into device mechanics and trigger events across a wide range of devices.
Enabling sustainability goals. We’re helping companies meet sustainability challenges by developing novel device designs to ISO 11608, incorporating reusable components, alternative power sources, and sustainable materials.
Explore how TTP is advancing next-generation drug delivery solutions, addressing challenges in high-viscosity mAbs and particulate suspensions through expertise in fluid dynamics, material science, and patient-focused design. Read more.
Accelerating respiratory drug delivery device design and development
Respiratory drug delivery requires alignment of formulation, aerosol science, device design and manufacturability to ensure consistent and effective dosing, patient ease-of-use, and scalable production. Each component influences the other - formulation impacts aerosol performance, which shapes device design, and manufacturability determines production feasibility. TTP’s expertise minimises risks, mitigates delays, and accelerates time to market by enabling optimisation across all areas.
We’ve developed more than 35 respiratory devices ranging from simple to advanced systems - including pMDIs, DPIs, soft mist inhalers, mesh nebulisers and nicotine delivery devices - many of which are now market-leading products.
With deep scientific understanding and cross-industry insight, we drive innovation in both next-generation devices and generics - even in crowded IP landscapes.
As respiratory drug delivery advances, we lead the way in developing technologies essential for future therapies like biologics, mRNA and other future therapies.
Discover how TTP’s TouchSpray™ atomiser technology revolutionised respiratory drug delivery, powering the PARI eFlow® nebuliser to cut treatment time by 50% while delivering 90% drug efficacy and unmatched portability for patients worldwide. Read more.
Drug delivery solutions for the unique challenges in cell and gene therapy
Cell and gene therapies represent a new frontier in precision medicine, offering targeted treatments with transformative potential. Yet, the path from concept to patient is complex.
Effective delivery of CRISPR therapies, viral vectors, and other advanced modalities often requires intricate drug delivery systems to reach precise targets and maintain efficacy throughout administration. At TTP, we recognise the distinct hurdles these therapies face.
With specialised facilities, stringent quality controls, and tailored approaches to drug stability and handling, we help you streamline the journey to market, saving time and mitigating risks and costs. Drawing on our decades of experience in drug delivery and device design, our multidisciplinary team works as your trusted partner to develop practical, scalable solutions.
Discover how TTP’s expertise in scalable drug delivery device design turns the complexities of R&D into a seamless, predictable process—minimising risks, aligning with manufacturing needs, and ensuring success from prototype to full-scale production. Read more.
How we can help
Requirements definition for next-generation platforms
Defining a next-generation platform means stepping into the unknown. TTP’s foundational scientific analysis and user needs research balance technical requirements with commercial goals, creating a robust, evidence-based foundation for development. Before building it right, we ensure you’re building the right thing.
Advancing patient-centric device development
Our multidisciplinary teams combine human factors experts and engineering expertise to design devices that meet both user needs and technical requirements.
Behavioural psychologists provide unique insights, supported by our hospital-simulated and in-home testing facilities, to capture real-world use cases and refine user experiences. This approach helps avoid common user challenges, delivering devices that enhance patient outcomes.
Quality-driven, risk management focus
Turning innovative technologies into leading medical devices demands robust risk and quality management at every stage.
At TTP, we evaluate both the operational and manufacturing capabilities of new technologies, seamlessly integrating them with validated solutions to reduce risk and maintain quality. Working within our ISO 13485 framework, we rigorously apply ISO 14971 standards to anticipate, manage, and mitigate potential device risks—ensuring each product meets high safety and reliability standards.
Accelerating drug delivery device development to clinical trial
Our extensive in-house capabilities, including scanning electron microscopy and a range of manufacturing processes from silicon etching to CNC machining, allow us to test and refine solutions quickly.
Our ISO 13485-certified low-volume manufacturing enables us to supply clinical trial samples, bridging the gap from development to full-scale production.
Developing drug delivery devices for high-volume manufacturing
High-volume manufacturing introduces additional requirements beyond user and commercial needs, demanding attention from the earliest development stages.
Through our strong relationships with medical manufacturers, we gain early insights into manufacturing challenges, ensuring a seamless transfer to production. Our in-house TTP Manufacturing team assesses risks and initiates the path to volume production, minimising surprises along the way.
Innovating sustainable drug delivery solutions
Sustainable design goes beyond recyclable packaging. From material choices to efficient manufacturing and product lifecycle planning, there are multiple levers to enhance your device's environmental impact. We’ll help you identify and optimise each one to align with your sustainability goals.
Requirements definition for next-generation platforms
Defining a next-generation platform means stepping into the unknown. TTP’s foundational scientific analysis and user needs research balance technical requirements with commercial goals, creating a robust, evidence-based foundation for development. Before building it right, we ensure you’re building the right thing.
Advancing patient-centric device development
Our multidisciplinary teams combine human factors experts and engineering expertise to design devices that meet both user needs and technical requirements.
Behavioural psychologists provide unique insights, supported by our hospital-simulated and in-home testing facilities, to capture real-world use cases and refine user experiences. This approach helps avoid common user challenges, delivering devices that enhance patient outcomes.
Quality-driven, risk management focus
Turning innovative technologies into leading medical devices demands robust risk and quality management at every stage.
At TTP, we evaluate both the operational and manufacturing capabilities of new technologies, seamlessly integrating them with validated solutions to reduce risk and maintain quality. Working within our ISO 13485 framework, we rigorously apply ISO 14971 standards to anticipate, manage, and mitigate potential device risks—ensuring each product meets high safety and reliability standards.
Accelerating drug delivery device development to clinical trial
Our extensive in-house capabilities, including scanning electron microscopy and a range of manufacturing processes from silicon etching to CNC machining, allow us to test and refine solutions quickly.
Our ISO 13485-certified low-volume manufacturing enables us to supply clinical trial samples, bridging the gap from development to full-scale production.
Developing drug delivery devices for high-volume manufacturing
High-volume manufacturing introduces additional requirements beyond user and commercial needs, demanding attention from the earliest development stages.
Through our strong relationships with medical manufacturers, we gain early insights into manufacturing challenges, ensuring a seamless transfer to production. Our in-house TTP Manufacturing team assesses risks and initiates the path to volume production, minimising surprises along the way.
Innovating sustainable drug delivery solutions
Sustainable design goes beyond recyclable packaging. From material choices to efficient manufacturing and product lifecycle planning, there are multiple levers to enhance your device's environmental impact. We’ll help you identify and optimise each one to align with your sustainability goals.
Our approach and capabilities
We deliver across the entire life of a project, from opportunity discovery to production engineering. Discover how our interdisciplinary teams of experts collaborate to tackle the toughest product development challenges.
Our campus and facilities
Our award-winning campus has been designed with a clear vision. To create a space which can support our people and our clients as we develop and deliver the very best technology solutions.
Software capability at TTP
Engaged in all stages of software and product development, our software capability at TTP covers the full spectrum—from in-depth analysis and system architecture to prototype design, implementation, and test development.
Manufacturing capability at TTP
Working seamlessly with our development teams, we take clients' products through prototype builds, clinical trials, pilot manufacture and more. Using TTP Manufacturing reduces uncertainty, risk and time to market for our clients.
Meet some of the team
Steve Gowers
Alex Lyness
Dan Lock
